EMA awards priority status to Bavarian Nordic's RSV vaccine for the over-60s

The priority status accelerates the approval process once phase III studies are complete.

Photo: Bavarian Nordic / PR

Danish vaccine company Bavarian Nordic has been awarded priority status in Europe for its RSV vaccine candidate, MVA-BN RSV.

The PRIME status that the European Medicines Agency (EMA) has awarded applies to recipients aged 60 or over.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs